Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (12 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (6)
Type
(
2 selected
)
Type
Guidance (367)
Quality standard (0)
Guidance programme
(
10 selected
)
Guidance programme
Antimicrobial prescribing guidelines (0)
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (10)
Medical technologies guidance (11)
NICE guidelines (30)
Public health guidelines (1)
Safe staffing guidelines (0)
Social care guidelines (0)
Technology appraisal guidance (301)
Apply filters
Showing 1 to 50 of 367
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Type: Quality standard
Remove Type: Quality standard filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance programme: Clinical guidelines
Remove Guidance programme: Clinical guidelines filter
Guidance programme: Medical technologies guidance
Remove Guidance programme: Medical technologies guidance filter
Guidance programme: Interventional procedures guidance
Remove Guidance programme: Interventional procedures guidance filter
Guidance programme: Diagnostics guidance
Remove Guidance programme: Diagnostics guidance filter
Guidance programme: Highly specialised technologies guidance
Remove Guidance programme: Highly specialised technologies guidance filter
Guidance programme: Public health guidelines
Remove Guidance programme: Public health guidelines filter
Guidance programme: Antimicrobial prescribing guidelines
Remove Guidance programme: Antimicrobial prescribing guidelines filter
Guidance programme: Safe staffing guidelines
Remove Guidance programme: Safe staffing guidelines filter
Guidance programme: Social care guidelines
Remove Guidance programme: Social care guidelines filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]
Technology appraisal guidance
12 February 2025
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]
Technology appraisal guidance
TBC
Abaloparatide for treating osteoporosis in postmenopausal women [ID882]
Technology appraisal guidance
7 August 2024
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]
Technology appraisal guidance
TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]
Technology appraisal guidance
TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533
Technology appraisal guidance
TBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Technology appraisal guidance
TBC
Acute kidney injury: prevention, detection and management - Assessing risk factors for acute kidney injury in adults having iodine-based contrast media
NICE guideline
16 October 2024
Adrenal insufficiency: identification and management
NICE guideline
28 August 2024
Alcohol-mediated perivascular renal denervation for resistant hypertension
Interventional procedures guidance
5 February 2025
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]
Technology appraisal guidance
11 December 2024
ALXN1840 for treating Wilson disease TS ID 9950
Technology appraisal guidance
TBC
Alzheimer's disease (early) - gantenerumab [ID6142]
Technology appraisal guidance
TBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer ID5110
Technology appraisal guidance
TBC
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256
Technology appraisal guidance
TBC
Amyotrophic lateral sclerosis - SAR443820 [ID6386]
Technology appraisal guidance
TBC
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]
Technology appraisal guidance
TBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]
Technology appraisal guidance
TBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
Highly specialised technology
TBC
Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathway
Health technology evaluation
TBC
Artificial intelligence software to help detect fractures in the emergency department (provisional title)
Health technology evaluation
17 December 2024
Asthma: diagnosis, monitoring and chronic asthma management
NICE guideline
27 November 2024
Asunercept for treating glioblastoma [1301]
Technology appraisal guidance
TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Technology appraisal guidance
TBC
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]
Technology appraisal guidance
TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]
Technology appraisal guidance
TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]
Technology appraisal guidance
TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
Technology appraisal guidance
TBC
Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma [ID6325]
Technology appraisal guidance
10 September 2025
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
Technology appraisal guidance
TBC
Avapritinib for treating advanced systemic mastocytosis ID3770
Technology appraisal guidance
TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
Technology appraisal guidance
TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
Technology appraisal guidance
TBC
Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143]
Technology appraisal guidance
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Technology appraisal guidance
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
Technology appraisal guidance
TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212
Technology appraisal guidance
5 March 2025
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211
Technology appraisal guidance
TBC
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Technology appraisal guidance
TBC
Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]
Technology appraisal guidance
TBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]
Technology appraisal guidance
TBC
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]
Technology appraisal guidance
20 February 2019
Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180]
Technology appraisal guidance
TBC
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]
Technology appraisal guidance
20 November 2024
Bipolar disorder: assessment and management (extraordinary review)
NICE guideline
TBC
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]
Technology appraisal guidance
TBC
Breast cancer guidelines
NICE guideline
TBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]
Technology appraisal guidance
13 November 2024
Current page
1
2
3
…
8
Page
1
of
8
Next page
Results per page
10
25
50
All
Back to top